Clinical Audit of screening Latent TB, Hepatitis-C, and Occult Hepatitis-B in Rheumatoid arthritis’ patients starting biologic or targeted synthetic DMARDS

This clinical audit emphasizes the need of thorough screening protocols with early detection and management of latent infections to optimize treatment outcomes in RA particularly in regions with specific infectious disease burdens like Pakistan. Our documentation of compliance with pre-screening was high but there remains room for improvement. We aim to clinical audit for reactivation of these infections also in future.